Splenic marginal zone lymphoma (SMZL) is an indolent B-cell tumor involving the spleen, and is characterized by recurrent deletion of chromosome 7q and biased usage of the immunoglobulin heavy variable (IGHV) allele 1-2*04.1 Genomic studies have partially unraveled the typical SMZL-coding genome, which is characterized by lesions affecting genes involved in the physiological homeostasis of marginal zone (MZ) B cells, including mutations of NOTCH2.2, 3, 4, 5 However, the full spectrum of lesions that contribute to the malignant transformation of SMZL remains unknown.

The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma / Piva, R; Deaglio, S; Famà, R; Buonincontri, R; Scarfò, I; Bruscaggin, A; Mereu, E; Serra, S; Spina, V; Brusa, D; Garaffo, G; Monti, S; Dal Bo, M; Marasca, Roberto; Arcaini, L; Neri, A; Gattei, V; Paulli, M; Tiacci, E; Bertoni, F; Pileri, Sa; Foà, R; Inghirami, G; Gaidano, G; Rossi, D.. - In: LEUKEMIA. - ISSN 0887-6924. - STAMPA. - 29:2(2015), pp. 503-507. [10.1038/leu.2014.294]

The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma

MARASCA, Roberto;
2015

Abstract

Splenic marginal zone lymphoma (SMZL) is an indolent B-cell tumor involving the spleen, and is characterized by recurrent deletion of chromosome 7q and biased usage of the immunoglobulin heavy variable (IGHV) allele 1-2*04.1 Genomic studies have partially unraveled the typical SMZL-coding genome, which is characterized by lesions affecting genes involved in the physiological homeostasis of marginal zone (MZ) B cells, including mutations of NOTCH2.2, 3, 4, 5 However, the full spectrum of lesions that contribute to the malignant transformation of SMZL remains unknown.
2015
6-ott-2014
29
2
503
507
The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma / Piva, R; Deaglio, S; Famà, R; Buonincontri, R; Scarfò, I; Bruscaggin, A; Mereu, E; Serra, S; Spina, V; Brusa, D; Garaffo, G; Monti, S; Dal Bo, M; Marasca, Roberto; Arcaini, L; Neri, A; Gattei, V; Paulli, M; Tiacci, E; Bertoni, F; Pileri, Sa; Foà, R; Inghirami, G; Gaidano, G; Rossi, D.. - In: LEUKEMIA. - ISSN 0887-6924. - STAMPA. - 29:2(2015), pp. 503-507. [10.1038/leu.2014.294]
Piva, R; Deaglio, S; Famà, R; Buonincontri, R; Scarfò, I; Bruscaggin, A; Mereu, E; Serra, S; Spina, V; Brusa, D; Garaffo, G; Monti, S; Dal Bo, M; Marasca, Roberto; Arcaini, L; Neri, A; Gattei, V; Paulli, M; Tiacci, E; Bertoni, F; Pileri, Sa; Foà, R; Inghirami, G; Gaidano, G; Rossi, D.
File in questo prodotto:
File Dimensione Formato  
leu2014294.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 1.06 MB
Formato Adobe PDF
1.06 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1081840
Citazioni
  • ???jsp.display-item.citation.pmc??? 35
  • Scopus 79
  • ???jsp.display-item.citation.isi??? 69
social impact